J&J Secures FDA 510(k) Clearance for MONARCH QUEST 3 Bronchoscopy System
核心洞察
Johnson & Johnson received FDA 510(k) clearance for the MONARCH QUEST 3 (搜索) bronchoscopy system, the fourth software launch for the platform in 18 months.
The update adds AI-powered nodule segmentation, improved registration and navigation accuracy, and a new 3D Compass overlay to address CT-to-body divergence during bronchoscopy.
MONARCH QUEST 3 (搜索) expands compatibility with mobile and fixed CBCT imaging systems and integrates with J&J's Polyphonic digital ecosystem for procedural review and collaboration.
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) 510(k) clearance for the MONARCH QUEST 3 (搜索) bronchoscopy system, the latest software update designed for its robotically-assisted MONARCH platform. The clearance marks the fourth software launch for the platform in 18 months, reflecting the company's stated goal of advancing its robotically-assisted bronchoscopy system.
The MONARCH platform is intended to provide flexible, robotically assisted visualization and access to patient airways for both diagnostic and therapeutic bronchoscope procedures. MONARCH QUEST 3 (搜索) introduces further enhancements to planning and navigation, helping clinicians address computed tomography (CT)-to-body divergence and anatomical changes that can occur during bronchoscopy.
AI-Powered Planning and Navigation Enhancements
MONARCH QUEST 3 (搜索) features AI-powered nodule segmentation intended to allow more accurate nodule boundary generation in pre-procedural planning. Additional enhancements include improved registration and navigation accuracy, as well as a new 3D Compass overlay designed to assist clinicians in orienting the bronchoscope tip in relation to patient anatomy.
The software update also increases compatibility with a range of mobile and fixed CBCT imaging systems, intended to help clinicians use existing imaging tools for targeting lung nodules and managing CT-to-body divergence. According to J&J, the system builds upon its ongoing enhancements to the MONARCH platform's AI-based planning and navigation capabilities, which have been guided by feedback from clinical users.
Digital Ecosystem Integration
The software update leverages J&J's digital ecosystem, Polyphonic, which enables procedural review, collaboration, and case analysis via a centralized video library. Polyphonic for MONARCH allows each case to be organized in a reviewable format to support learning and teamwork.
J&J MedTech MONARCH president Aleksandra Popovic said: "Being first to market carries a responsibility to keep advancing. With MONARCH QUEST 3 (搜索), we're continuing to evolve the MONARCH platform in close partnership with clinicians, applying artificial intelligence, expanding imaging integration, and delivering software enhancements that support greater procedural confidence and precision for patients."
Clinical Significance in Lung Cancer
The MONARCH platform addresses a significant unmet need in lung cancer (搜索) diagnosis. Lung cancer remains a leading cause of cancer-related mortality, in part because it is often diagnosed at a late stage when treatment options are limited. Nearly half of early-stage lesions are located in the periphery of the lung, which is difficult to reach with traditional bronchoscopy.
If diagnosed at an early stage of lung cancer (搜索), up to 90% of people survive at least 5 years; if diagnosed at a late stage, 5-year survival can be less than 10%. The ability to reach and biopsy lung nodules at an earlier stage with tools like the MONARCH platform represents a leap forward in interventional care for patients, helping care teams get patients into the treatment pathway faster.
Dr. Zaid Zoumot, Interventional Pulmonologist and Division Chair, Pulmonary Medicine, Cleveland Clinic Abu Dhabi, said: "Robotically-assisted bronchoscopy represents a breakthrough in how we detect and diagnose lung disease. With this technology, we can reach small lesions in all segments of the lung, which creates the opportunity to accelerate treatment decisions." In a clinical evaluation, 679 patients received a robotic-assisted bronchoscopy with median lesion size 18.5 (13.5-26.5) mm and median distance from pleural surface 5 (0-16) mm.
Safety Information
Complications associated with bronchoscopy may include breathing difficulties, infection, low blood oxygen, or more serious issues such as collapsed lung or cardiac arrhythmia, according to the provided safety information. Additional complications from bronchoscopy may include vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, bleeding from the biopsied site, or an allergic reaction to medications.
In July 2026, J&J achieved Q2 revenues totalling around $25.3bn, representing a year-over-year uptick of 6.6%, with J&J MedTech accounting for more than a third of the total.